The Seattle Genetics is significantly influencing the lives of many people. Giving hope to the many families who don’t give up hope of their loved ones being well again. The team of dedicated scientists has positively impacted the health of their patients who are always on the forefront of every research they conduct. Whatever they do, they do it with the patients in mind and the desire to elongate their lives, so that they can continue being productive in the society.
The biotech company uses miRNAs. The miRNAs code with the human genome and then use them as natural regulators of the global gene expression. Since each of the miRNAs regulates many more different genes; tens of thousands, they may act as the master switch, and they effectively affect the functioning and processes of multiple cellular pathways.
The multiple miRNAs in their portfolio have applications in Oncology and other diseases. The oncology-directed miRNAs include the miR-34 and let-7, cancer suppressors that have been effective in blocking tumor growth. The company, due to its impact on human life and more so their health has received funding from many private investors through the emerging technology fund and from the Cancer Prevention and Research Institute of Texas.
The president and chief executive officer
Dr. Clay B. Siegall was appointed the chief director of the Seattle Genetics; being one of its co-founders, and a renowned doctor, he sure had the knowledge of all the company does. He has not only contributed in the leaders but also in the development of the technology and in impacting the lives of the people of Texas. Through his leadership, the Seattle Genetics has acquired multiple licenses for their technology (ADC), e.g. the Genentech, AbbVie, GlaxoSmithKline and Pfizer that generate more than $ 300 million for the company. He has led the company in capital-raising activities through the public and private financing. Not forgetting his impact on patients’ lives which is based on his innovativeness, vigorous research, drug development practices, but more so his passion for helping patients. His efforts have led the company through his leadership in the development of antibody-drug conjugates ADCs for cancer treatment.